TUBA4B
gene geneOn this page
Also known as FLJ13940
Summary
TUBA4B (tubulin alpha 4b, HGNC:18637) is a protein-coding gene on chromosome 2q35, encoding Tubulin-like protein alpha-4B (Q9H853). Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed ofalpha- and beta-tubulin heterodimers.
Predicted to enable GTP binding activity; hydrolase activity; and metal ion binding activity. Predicted to be a structural constituent of cytoskeleton. Predicted to be involved in cytoskeleton organization and microtubule-based process. Predicted to be located in cytoplasm and microtubule.
Source: NCBI Gene 80086 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 3 total
- Druggable target: yes
- MANE Select transcript:
NM_001355221
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:18637 |
| Approved symbol | TUBA4B |
| Name | tubulin alpha 4b |
| Location | 2q35 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ13940 |
| Ensembl gene | ENSG00000243910 |
| Ensembl biotype | protein_coding |
| Entrez | 80086 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 2 protein_coding_CDS_not_defined, 2 protein_coding
ENST00000473885, ENST00000485041, ENST00000490341, ENST00000713556
RefSeq mRNA: 1 — MANE Select: NM_001355221
NM_001355221
CCDS: CCDS86922
Canonical transcript exons
ENST00000490341 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002247466 | 219266521 | 219266566 |
| ENSE00002283895 | 219270202 | 219270335 |
| ENSE00002302786 | 219271166 | 219272197 |
| ENSE00003775756 | 219253243 | 219253419 |
Expression profiles
Bgee: expression breadth ubiquitous, 190 present calls, max score 97.83.
Top tissues by expression
237 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right uterine tube | UBERON:0001302 | 97.83 | gold quality |
| epithelium of bronchus | UBERON:0002031 | 96.31 | gold quality |
| bronchial epithelial cell | CL:0002328 | 95.74 | gold quality |
| bronchus | UBERON:0002185 | 95.67 | gold quality |
| oocyte | CL:0000023 | 95.04 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 94.05 | gold quality |
| type B pancreatic cell | CL:0000169 | 92.05 | gold quality |
| olfactory bulb | UBERON:0002264 | 91.68 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 91.52 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 90.53 | gold quality |
| secondary oocyte | CL:0000655 | 89.71 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 88.77 | gold quality |
| diaphragm | UBERON:0001103 | 86.36 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 84.12 | silver quality |
| fallopian tube | UBERON:0003889 | 82.94 | gold quality |
| oviduct epithelium | UBERON:0004804 | 82.74 | gold quality |
| gingival epithelium | UBERON:0001949 | 82.66 | silver quality |
| gluteal muscle | UBERON:0002000 | 81.94 | silver quality |
| hair follicle | UBERON:0002073 | 81.69 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 80.52 | gold quality |
| gingiva | UBERON:0001828 | 79.78 | silver quality |
| trachea | UBERON:0003126 | 79.40 | gold quality |
| upper arm skin | UBERON:0004263 | 76.65 | silver quality |
| cervix squamous epithelium | UBERON:0006922 | 76.25 | gold quality |
| caput epididymis | UBERON:0004358 | 75.65 | gold quality |
| squamous epithelium | UBERON:0006914 | 75.12 | silver quality |
| amniotic fluid | UBERON:0000173 | 74.69 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 74.40 | gold quality |
| deltoid | UBERON:0001476 | 74.00 | silver quality |
| biceps brachii | UBERON:0001507 | 73.82 | silver quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-10287 | yes | 26.97 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 4)
- A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. (PMID:22360420)
- Low expression TUBA4B in NSCLC tissue. (PMID:27411923)
- The low expression of TUBA4B was significantly associated with poor overall survival, disease-free survival, and recurrence-free survival in cancer patients. (PMID:30157490)
- Low expression of lncRNA TUBA4B promotes proliferation and inhibits apoptosis of colorectal cancer cells via regulating P15 and P16 expressions. (PMID:32271419)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tuba2 | ENSDARG00000045014 |
| caenorhabditis_elegans | WBGENE00003175 |
Paralogs (23): TUBG2 (ENSG00000037042), TUBE1 (ENSG00000074935), TUBA3D (ENSG00000075886), TUBB1 (ENSG00000101162), TUBB4A (ENSG00000104833), TUBD1 (ENSG00000108423), TUBA1B (ENSG00000123416), TUBA4A (ENSG00000127824), TUBG1 (ENSG00000131462), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBA3E (ENSG00000152086), TUBA1A (ENSG00000167552), TUBA1C (ENSG00000167553), TUBB8B (ENSG00000173213), TUBB6 (ENSG00000176014), TUBAL3 (ENSG00000178462), TUBA8 (ENSG00000183785), TUBB4B (ENSG00000188229), TUBB (ENSG00000196230), TUBA3C (ENSG00000198033), TUBB3 (ENSG00000258947), TUBB8 (ENSG00000261456)
Protein
Protein identifiers
Tubulin-like protein alpha-4B — Q9H853 (reviewed: Q9H853)
Alternative names: Alpha-tubulin 4B
All UniProt accessions (2): Q9H853, A0AAA9YHK8
UniProt curated annotations — full annotation on UniProt →
Function. Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed ofalpha- and beta-tubulin heterodimers.
Subcellular location. Cytoplasm. Cytoskeleton.
Post-translational modifications. Some glutamate residues at the C-terminus are polyglutamylated, resulting in polyglutamate chains on the gamma-carboxyl group. Polyglutamylation plays a key role in microtubule severing by spastin (SPAST). SPAST preferentially recognizes and acts on microtubules decorated with short polyglutamate tails: severing activity by SPAST increases as the number of glutamates per tubulin rises from one to eight, but decreases beyond this glutamylation threshold. Glutamylation is also involved in cilia motility. Some glutamate residues at the C-terminus are monoglycylated but not polyglycylated due to the absence of functional TTLL10 in human. Monoglycylation is mainly limited to tubulin incorporated into cilia and flagella axonemes, which is required for their stability and maintenance. Flagella glycylation controls sperm motility. Both polyglutamylation and monoglycylation can coexist on the same protein on adjacent residues, and lowering glycylation levels increases polyglutamylation, and reciprocally.
Similarity. Belongs to the tubulin family.
RefSeq proteins (1): NP_001342150* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000217 | Tubulin | Family |
| IPR002452 | Alpha_tubulin | Family |
| IPR003008 | Tubulin_FtsZ_GTPase | Domain |
| IPR036525 | Tubulin/FtsZ_GTPase_sf | Homologous_superfamily |
Pfam: PF00091
Catalyzed reactions (Rhea), 1 shown:
- GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)
UniProt features (16 total): binding site 8, sequence conflict 3, compositionally biased region 2, chain 1, region of interest 1, active site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9H853-F1 | 71.58 | 0.18 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1): 193
Ligand- & substrate-binding residues (8): 118; 145; 167; 10; 10; 79; 83; 84
Function
Pathways and Gene Ontology
Reactome pathways
79 pathways
| ID | Pathway |
|---|---|
| R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane |
| R-HSA-190840 | Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane |
| R-HSA-190861 | Gap junction assembly |
| R-HSA-2132295 | MHC class II antigen presentation |
| R-HSA-2467813 | Separation of Sister Chromatids |
| R-HSA-2500257 | Resolution of Sister Chromatid Cohesion |
| R-HSA-3371497 | HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes |
| R-HSA-389960 | Formation of tubulin folding intermediates by CCT/TriC |
| R-HSA-389977 | Post-chaperonin tubulin folding pathway |
| R-HSA-437239 | Recycling pathway of L1 |
| R-HSA-5626467 | RHO GTPases activate IQGAPs |
| R-HSA-5663220 | RHO GTPases Activate Formins |
| R-HSA-6807878 | COPI-mediated anterograde transport |
| R-HSA-6811434 | COPI-dependent Golgi-to-ER retrograde traffic |
| R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic |
| R-HSA-68877 | Mitotic Prometaphase |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint |
| R-HSA-8955332 | Carboxyterminal post-translational modifications of tubulin |
| R-HSA-9609690 | HCMV Early Events |
| R-HSA-9609736 | Assembly and cell surface presentation of NMDA receptors |
| R-HSA-9619483 | Activation of AMPK downstream of NMDARs |
| R-HSA-9646399 | Aggrephagy |
| R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation |
| R-HSA-9668328 | Sealing of the nuclear envelope (NE) by ESCRT-III |
| R-HSA-983189 | Kinesins |
| R-HSA-9833482 | PKR-mediated signaling |
| R-HSA-109582 | Hemostasis |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission |
| R-HSA-112315 | Transmission across Chemical Synapses |
MSigDB gene sets: 148 (showing top):
AP1_01, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, LFA1_Q6, AREB6_01, REACTOME_MEMBRANE_TRAFFICKING, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, MYOD_01, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, MYCMAX_01, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, ARGGGTTAA_UNKNOWN, TGANTCA_AP1_C, NRF2_Q4
GO Biological Process (2): microtubule-based process (GO:0007017), cytoskeleton organization (GO:0007010)
GO Molecular Function (5): structural constituent of cytoskeleton (GO:0005200), GTP binding (GO:0005525), hydrolase activity (GO:0016787), metal ion binding (GO:0046872), nucleotide binding (GO:0000166)
GO Cellular Component (4): microtubule (GO:0005874), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), microtubule cytoskeleton (GO:0015630)
Reactome top-level categories
Rollup of top-17 pathways:
| Category | Pathways |
|---|---|
| Mitotic Prometaphase | 2 |
| RHO GTPase Effectors | 2 |
| Golgi-to-ER retrograde transport | 2 |
| Membrane Trafficking | 1 |
| Transport of connexons to the plasma membrane | 1 |
| Gap junction trafficking | 1 |
| Adaptive Immune System | 1 |
| Mitotic Anaphase | 1 |
| Cellular responses to stress | 1 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 1 |
| Protein folding | 1 |
| L1CAM interactions | 1 |
| ER to Golgi Anterograde Transport | 1 |
| M Phase | 1 |
| G2/M Transition | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoskeleton | 2 |
| cellular process | 1 |
| organelle organization | 1 |
| structural molecule activity | 1 |
| cytoskeleton organization | 1 |
| guanyl ribonucleotide binding | 1 |
| purine ribonucleoside triphosphate binding | 1 |
| catalytic activity | 1 |
| cation binding | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| microtubule cytoskeleton | 1 |
| polymeric cytoskeletal fiber | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
2968 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TUBA4B | NBEA | Q8NFP9 | 460 |
| TUBA4B | C11orf16 | Q9NQ32 | 431 |
| TUBA4B | OR1M1 | Q8NGA1 | 370 |
| TUBA4B | TUBGCP2 | Q9BSJ2 | 348 |
| TUBA4B | OR2Z1 | Q8NG97 | 294 |
| TUBA4B | CLXN | Q9HAE3 | 277 |
| TUBA4B | GARNL3 | Q5VVW2 | 269 |
| TUBA4B | TEKT1 | Q969V4 | 268 |
| TUBA4B | TMEM106A | Q96A25 | 265 |
| TUBA4B | MYO9A | B2RTY4 | 247 |
| TUBA4B | NACA2 | Q9H009 | 246 |
| TUBA4B | TUBGCP6 | Q96RT7 | 225 |
| TUBA4B | NOCT | Q9UK39 | 225 |
| TUBA4B | TUBGCP4 | Q9UGJ1 | 223 |
| TUBA4B | TUBGCP3 | Q96CW5 | 223 |
| TUBA4B | CFAP65 | Q6ZU64 | 223 |
| TUBA4B | ZSCAN12 | O43309 | 223 |
IntAct
19 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| KATNAL1 | CDK1 | psi-mi:“MI:0914”(association) | 0.350 |
| CUL4A | HAX1 | psi-mi:“MI:0914”(association) | 0.350 |
| CUL3 | PXDNL | psi-mi:“MI:0914”(association) | 0.350 |
| CUL5 | DDX3X | psi-mi:“MI:0914”(association) | 0.350 |
| L | MYO1C | psi-mi:“MI:0914”(association) | 0.350 |
| BMI1 | MEIS3P1 | psi-mi:“MI:0914”(association) | 0.350 |
| IQCB1 | PCP4L1 | psi-mi:“MI:0914”(association) | 0.350 |
| PPP4R1L | IFT56 | psi-mi:“MI:0914”(association) | 0.350 |
| PRKY | METTL15 | psi-mi:“MI:0914”(association) | 0.350 |
| ERBB2 | DNM1L | psi-mi:“MI:0914”(association) | 0.350 |
| STAT3 | IDH3B | psi-mi:“MI:0914”(association) | 0.350 |
| ATF3 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| FOS | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| GATA2 | C11orf98 | psi-mi:“MI:0914”(association) | 0.350 |
| CASP3 | NACA | psi-mi:“MI:0914”(association) | 0.350 |
| FOS | C11orf98 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC38A1 | XPOT | psi-mi:“MI:0914”(association) | 0.350 |
| IKBKG | TUBA4B | psi-mi:“MI:0915”(physical association) | 0.000 |
ESM2 similar proteins: A0AAL4, A2AQ07, A6NHL2, P04688, P04689, P06606, P07304, P07436, P08070, P08841, P09207, P09643, P09645, P12460, P20364, P24633, P24634, P25862, P29502, P29514, P31017, P32255, P32256, P32925, P32928, P33624, P33631, P34475, P41385, P41386, P46264, P50260, P50719, P52274, P53371, P53372, P86221, P91910, P92120, Q39697
Diamond homologs: A0A644F0Y1, O49068, O93807, P18695, P23257, P23258, P23330, P25295, P32348, P34785, P34786, P34787, P38557, P38558, P40633, P42271, P53377, P53378, P54401, P54402, P54403, P54404, P54405, P83887, P83888, P90548, Q0VCD2, Q32KM1, Q39582, Q41807, Q41808, Q41874, Q4P235, Q55AR3, Q6DIM3, Q6FNU9, Q75A43, Q7Z9Z2, Q8HZV4, Q8J1R4
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| ATAT1 | “up-regulates quantity by stabilization” | TUBA4B | acetylation |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| intrinsic apoptotic signaling pathway | 5 | 69.0× | 4e-06 |
| positive regulation of gene expression | 6 | 8.9× | 4e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
3 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1107 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 2:219253852:TCA:T | donor_loss | 1.0000 |
| 2:219253853:CA:C | donor_loss | 1.0000 |
| 2:219253854:A:AC | donor_gain | 1.0000 |
| 2:219253854:A:T | donor_loss | 1.0000 |
| 2:219253855:C:CA | donor_loss | 1.0000 |
| 2:219253855:C:CC | donor_gain | 1.0000 |
| 2:219270332:GCTG:G | donor_gain | 1.0000 |
| 2:219270342:A:T | donor_gain | 1.0000 |
| 2:219253298:G:GT | donor_gain | 0.9900 |
| 2:219253342:GGTGC:G | donor_gain | 0.9900 |
| 2:219253854:AC:A | donor_gain | 0.9900 |
| 2:219253855:CC:C | donor_gain | 0.9900 |
| 2:219253855:CCA:C | donor_gain | 0.9900 |
| 2:219253855:CCATG:C | donor_gain | 0.9900 |
| 2:219270329:G:GT | donor_gain | 0.9900 |
| 2:219270334:TGGT:T | donor_loss | 0.9900 |
| 2:219270336:G:GA | donor_loss | 0.9900 |
| 2:219270336:G:GG | donor_gain | 0.9900 |
| 2:219270337:TGA:T | donor_loss | 0.9900 |
| 2:219270338:GAG:G | donor_loss | 0.9900 |
| 2:219253331:C:G | donor_gain | 0.9800 |
| 2:219253343:GTGC:G | donor_gain | 0.9800 |
| 2:219253344:TGCT:T | donor_gain | 0.9800 |
| 2:219253345:GCTG:G | donor_gain | 0.9800 |
| 2:219253855:CCAT:C | donor_gain | 0.9800 |
| 2:219270341:G:GT | donor_gain | 0.9800 |
| 2:219271165:GGCT:G | acceptor_gain | 0.9800 |
| 2:219270228:G:C | acceptor_gain | 0.9700 |
| 2:219271164:A:AG | acceptor_gain | 0.9700 |
| 2:219271165:G:GG | acceptor_gain | 0.9700 |
AlphaMissense
1576 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 2:219271193:T:C | F74L | 0.842 |
| 2:219271195:C:A | F74L | 0.842 |
| 2:219271195:C:G | F74L | 0.842 |
| 2:219271295:T:C | F108L | 0.837 |
| 2:219271297:C:A | F108L | 0.837 |
| 2:219271297:C:G | F108L | 0.837 |
| 2:219271520:T:C | F183L | 0.791 |
| 2:219271522:T:A | F183L | 0.791 |
| 2:219271522:T:G | F183L | 0.791 |
| 2:219271394:T:C | F141L | 0.769 |
| 2:219271396:C:A | F141L | 0.769 |
| 2:219271396:C:G | F141L | 0.769 |
| 2:219271202:T:C | F77L | 0.752 |
| 2:219271204:C:A | F77L | 0.752 |
| 2:219271204:C:G | F77L | 0.752 |
| 2:219271553:T:C | F194L | 0.714 |
| 2:219271555:C:A | F194L | 0.714 |
| 2:219271555:C:G | F194L | 0.714 |
| 2:219270219:T:C | F26L | 0.689 |
| 2:219270221:C:A | F26L | 0.689 |
| 2:219270221:C:G | F26L | 0.689 |
dbSNP variants (sampled 300 via entrez): RS1000084278 (2:219257378 C>T), RS1000850288 (2:219268687 G>C), RS1000897360 (2:219265239 G>A), RS1000928012 (2:219265566 G>A), RS1000992129 (2:219263004 G>A), RS1001055240 (2:219252410 C>T), RS1001119991 (2:219255694 C>T), RS1001221202 (2:219264013 A>G), RS1001281208 (2:219269016 A>G), RS1001488455 (2:219257931 G>A), RS1001569636 (2:219270332 G>A), RS1001842617 (2:219271910 C>CT), RS1001855611 (2:219257743 G>A), RS1001899535 (2:219266762 G>T), RS1001921760 (2:219252756 C>T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004616_133 | Platelet distribution width | 1.000000e-35 |
| GCST006137_6 | Serum folate levels | 5.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007984 | platelet component distribution width |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL4295944 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
13 total (human), top 13 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Aflatoxin B1 | affects expression, increases expression | 4 |
| Benzo(a)pyrene | increases expression | 3 |
| lasiocarpine | increases expression | 1 |
| 1,6-hexamethylene diisocyanate | increases methylation | 1 |
| Leflunomide | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Fluorouracil | affects reaction, decreases expression | 1 |
| Silicon Dioxide | increases expression | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
| Valproic Acid | increases expression | 1 |
| Cyclosporine | decreases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL4270855 | Binding | Binding affinity to tubulin beta-4B chain in human Hela cells lysates assessed as protein enrichment by measuring normalized heavy/light ratio at by nano-LC-ESIMS/MS analysis | Determination of Gymnemic Acid I as a Protein Biosynthesis Inhibitor Using Chemical Proteomics. — J Nat Prod |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.